Paul Miranda, MD

Board-Certified in Family Medicine · Emergency Physician · Obesity Medicine Association member

I’m an emergency and Family Medicine physician in Chattanooga, Tennessee, and founder of Summit Metabolic Health. I read every patient chart personally. This article reports on a topic patients keep asking about — it is education, not an endorsement.

Medically reviewed by Paul Miranda, MD

I’m Dr. Paul Miranda. I work ER shifts here in Chattanooga, and I run Summit Metabolic Health, a physician-led telehealth practice based in this city. Patients ask me some version of this question in almost every consult: if I start Ozempic, am I stuck on it forever, or will I gain everything back the day I stop? Here’s the honest part: the trial data say most people do regain weight after stopping a GLP-1 cold. That is real. But it is a dosing-protocol failure, not an inevitable outcome, and the distinction is the entire reason Summit built a step-down plan instead of a cutoff.

The fear is not irrational, and I will not tell you it is. Semaglutide works by mimicking a gut hormone that signals the hypothalamus to turn appetite down. Specifically, GLP-1 receptor agonism acts on the arcuate nucleus, suppressing hunger-driving AgRP neurons and activating the appetite-suppressing POMC/CART pathway (Drucker, Cell Metabolism, 2018). While the drug is on board, that signal is amplified well past what your body produces on its own.

Stop the drug abruptly, and that amplified signal disappears overnight. Nothing about your biology has been retrained. The hypothalamus goes back to defending the same set point it defended before you started. Hunger returns, often within days. That is not a willpower collapse. That is a signal being switched off.

I would rather you hear the numbers from me than discover them six months into a program that never mentioned them. In the STEP 1 withdrawal extension, patients who stopped semaglutide after 68 weeks of treatment regained roughly two-thirds of their lost weight within a year off the drug, with blood pressure and blood glucose drifting back toward baseline alongside it.

Tirzepatide tells the same story from a different angle. The SURMOUNT-1 176-week extension data show that patients who stayed on physician-titrated treatment kept their weight loss essentially intact for over three years. The patients who lost the most and kept it off were not the ones who stopped fastest. They were the ones whose treatment kept being managed.

Put those two data sets side by side and the conclusion is not “the drug doesn’t work.” It’s “the drug works for as long as someone is managing the dose, and stopping without a plan removes the thing that was working.”

Read the STEP 1 numbers again and ask what actually happened to those patients. They didn’t fail. Their treatment stopped. The trial protocol for a cold stop is the same cold stop most patients get when a subscription lapses, a prior authorization falls through, or a program simply doesn’t have a plan for what comes after goal weight.

This is why I push back when a patient tells me they “failed” Ozempic because the weight came back. You cannot fail a hormone. Hunger returning when a hormonal signal is withdrawn is physiology doing exactly what physiology does. The actual failure sits one level up, in a treatment model with no exit plan — which is exactly what I cover in more depth in how to stop Ozempic without regaining the weight.

At Summit, stopping is never a cliff. When a patient nears goal weight, I build a descending-dose step-down: the dose comes down in stages over weeks, not in one final injection followed by silence. I watch weight weekly during the taper, along with hunger reports and, when indicated, metabolic labs. If the scale moves the wrong direction, we catch it at two or three pounds, not twenty.

I review every chart myself before a taper starts and at every step down. This is not a form that triggers an automated dose change. It is a physician looking at your actual trajectory and deciding, with you, whether this is the week to step down further or the week to hold. That’s the same principle behind the plan I lay out for patients who’ve already reached goal weight and want to know what maintenance actually looks like long-term, in GLP-1 maintenance after goal weight.

Most of the national GLP-1 telehealth names you have seen advertised — Ro, Hims/Hers, Henry Meds, and Calibrate among them — run on an app-based intake model: a form, an async chat, a prescription. None of them puts a named physician on your chart managing a taper. Nobody is deciding when your dose should step down, because nobody is assigned to look.

That model works fine for getting a prescription filled. It has no answer for the question this article is about, because a taper is a clinical decision, not a checkout flow. A checkbox you clicked yourself is not the same as a physician reviewing your actual weight trend and telling you whether this month is safe to step down. I wrote more about that gap directly in physician-supervised care versus a telehealth mill, and it is the same gap that shows up the moment a patient tries to stop.

I am a board-certified physician, and at Summit I personally review every chart — not a questionnaire run through software, not a nurse queue, and not an app deciding your dose for you.

Before you start any GLP-1, whether at Summit or anywhere else, ask three questions. Who is managing my dose changes, and are they a physician? What does the taper look like when I reach goal weight — is there one, in writing, or does the plan end at “you’ll figure it out”? And what happens to my prescription if I need to pause, whether for cost, side effects, or life getting in the way?

If a program can’t answer those three questions before you’ve paid them anything, you already have your answer about what happens when you try to stop. The exit plan needs to exist before the first dose, not get improvised after the last one.

Stopping Ozempic does not have to mean losing what you worked for. The regain most people experience is a predictable result of an unmanaged cold stop, and it is preventable with a taper someone is actually watching. If you’re in Chattanooga and thinking about starting a GLP-1, or you’re already on one and wondering what the exit looks like, that conversation is worth having before you’re the one staring at the scale six months from now. Read more on the biology and the protocols behind it on the Summit Metabolic Health blog.

Ready to start? Apply at summitmetabolichealth.com/apply.

This post is for educational purposes only and does not constitute medical advice. Individual results vary. Consult a qualified physician before starting, stopping, or changing any medication.